Group 1 - ARCA biopharma has declared a special cash dividend estimated at $1.59 per share in connection with its merger with Oruka Therapeutics [1][2] - The special dividend will be payable to stockholders of record as of August 26, 2024, with a payment date scheduled for August 28, 2024 [2][3] - The payment of the special dividend is contingent upon ARCA stockholder approval of the merger, which will be voted on at a special meeting on August 22, 2024 [3] Group 2 - ARCA biopharma focuses on developing genetically and targeted therapies for cardiovascular diseases through a precision medicine approach [4] - Oruka Therapeutics is developing novel biologics aimed at treating chronic skin diseases, with a mission to achieve high rates of complete disease clearance for conditions like plaque psoriasis [5]
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics